Stage I Multiple Myeloma Treatment (IFM-01-04)
|ClinicalTrials.gov Identifier: NCT00733538|
Recruitment Status : Unknown
Verified February 2009 by Centre Hospitalier Universitaire de Nice.
Recruitment status was: Active, not recruiting
First Posted : August 13, 2008
Last Update Posted : March 26, 2012
- Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.
- Describe different progression's type noticed and define the prognosis factors of a fast evolution.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: zometa||Phase 4|
Multiple Myeloma in spite of therapy progresses mainly due to stem cell auto transplant, still remain a deadly disease. About 2000 new cases are diagnosed every year in France. The asymptomatic Stage I MM according to Duries and Salmon's staging are usually only watch over and only treated at progression. Zoledronate is a third generation aminobiphosphonate (BP), probably the most powerful among the available compounds which received market clearance authorisation in MM with bone damage. During MM, bone's hyper resorption is premature. Interactions exist between tumor growth and bone lyses. Zoledronate's got a proper antimyeloma's action (induce plasma cells apoptosis). We propose to test the early use of Zoledronate as soon as stage I MM to delay progression.
- PRINCIPAL: Assessment of survival without progression stage I MM in two groups: A arm: simple survey and B arm: administration of BP.
- SECONDARY: Describe different progression's type noticed (bone/extra bone) and define the prognosis factor of a fast stage I MM evolution (standard factors, cytogenetic 13 deletion, bone's restructuring strains: crosslaps, bone alkaline phosphatase), list side effects.
Multicenter international randomised trial, open labelled, with individual profit.
Intergroupe Francophone du Myélome's centers.
Asymptomatic stage I MM without bone's lesion on the standard radiographs.
After checking inclusion and non inclusion specifications, the patient will be included in the study and randomized (A arm or B arm) before all treatment. The randomisation will be done by center and stratified according to the diagnostic date witch a year or not.
- Arm A: simple survey as standard practice.
- Arm B: a 15 minutes infusion of Zoledronate every month until progression or a maximum of 18 infusions if no progression. The exams are the one usually defined according to good clinical practices guidelines besides cytogenetic, bone's restructuring strain and serum creatin dosage before each infusion in B arm.
The minimum number of patients required showing a median survival time increase without progression of 26 months in the control arm and 38 months in the BP arm is about 175 patients in each arm for a 48 months inclusion's period, and a monitoring of 24 months after the last inclusion (i.e. a study's length of 6 years).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||350 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||Stage I Multiple Myeloma Treatment|
|Study Start Date :||December 2004|
|Primary Completion Date :||November 2009|
|Estimated Study Completion Date :||November 2012|
U.S. FDA Resources
Active Comparator: 1
patients receiving zometa treatment
patients receiving treatment during their follow-up
No Intervention: 2
No treatment, just follow-up
- Survival without progress [ Time Frame: every month during 6 years ]
- predictive factors of a fast evolution of multiple myeloma [ Time Frame: every month during 6 years ]
- Secondary effects of zolédronate [ Time Frame: every month during six years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733538
|Service de Medecine interne, Hôpital l'ARCHET, CHU de Nice|
|Nice, France, 06202|
|Principal Investigator:||Jean-Gabriel FUZIBET, PU-PH||service de médecine interne, CHU de Nice|